title: Expression of NAD(P)H oxidase subunits and their contribution to cardiovascular damage in aldosterone/salt-induced hypertensive rat.
abstract: NAD(P)H oxidase plays an important role in hypertension and its complication in aldosterone-salt rat. We questioned whether NAD(P)H oxidase subunit expression and activity are modulated by aldosterone and whether this is associated with target-organ damage. Rats were infused with aldosterone (0.75 microg/hr/day) for 6 weeks and were given 0.9% NaCl+/-losartan (30 mg/kg/day), spironolactone (200 mg/kg/day), and apocynin (1.5 mM/L). Aldosterone-salt hypertension was prevented completely by spironolactone and modestly by losartan and apocynin. Aldosterone increased aortic NAD(P)H oxidase activity by 34% and spironolactone and losartan inhibited the activity. Aortic expression of the subunits p47(phox), gp91(phox), and p22(phox) increased in aldosterone-infused rats by 5.5, 4.7, and 3.2-fold, respectively, which was decreased completely by spironolactone and partially by losartan and apocynin. Therefore, the increased expression of NAD(P)H oxidase may contribute to cardiovascular damage in aldosterone-salt hypertension through the increased expression of each subunit.
authors.affiliation: Samsung Biomedical Research Institutue, Ottawa Health Research Institute, University of Ottawa, Ottawa, Canada.
authors.forename: Young Mee
authors.initials: YM
authors.lastname: Park
authors.forename: Bong Hee
authors.initials: BH
authors.lastname: Lim
authors.forename: Rhian M
authors.initials: RM
authors.lastname: Touyz
authors.forename: Jeong Bae
authors.initials: JB
authors.lastname: Park
mesh_terms: D000098:Acetophenones / Q000008:administration & dosage; D000450:Aldosterone / Q000008:administration & dosage / Q000633:toxicity*; D047228:Angiotensin II Type 1 Receptor Blockers / Q000008:administration & dosage; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage; D001011:Aorta / Q000378:metabolism / Q000473:pathology; D001794:Blood Pressure / Q000187:drug effects; D006973:Hypertension / Q000139:chemically induced / Q000188:drug therapy / Q000201:enzymology*; D007668:Kidney / Q000378:metabolism / Q000473:pathology; D019808:Losartan / Q000008:administration & dosage; D008297:Male; D000451:Mineralocorticoid Receptor Antagonists / Q000008:administration & dosage; D019255:NADPH Oxidases / Q000037:antagonists & inhibitors / Q000378:metabolism*; D009929:Organ Size; D018384:Oxidative Stress; D021122:Protein Subunits / Q000378:metabolism; D012333:RNA, Messenger / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D012965:Sodium Chloride / Q000008:administration & dosage; D013148:Spironolactone / Q000008:administration & dosage; D013481:Superoxides / Q000378:metabolism
chemical_list: D000098:Acetophenones; D047228:Angiotensin II Type 1 Receptor Blockers; D000894:Anti-Inflammatory Agents, Non-Steroidal; D000451:Mineralocorticoid Receptor Antagonists; D021122:Protein Subunits; D012333:RNA, Messenger; D013481:Superoxides; D013148:Spironolactone; D012965:Sodium Chloride; D000450:Aldosterone; C056165:acetovanillone; D019255:NADPH Oxidases; D019808:Losartan